Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AGAINST

Financiado

Achieving the golden Grail in solid tumor treatment

Macrophage therapy is promising for solid tumor treatment as these cells are continuously recruited into the tumor mass, even the most hypoxic regions. Our pioneering research demonstrated that macrophages are able to take up ferr... ver más

31/03/2025

SGGW WARSAW UNIVER...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

SZKOLA GLOWNA GOSPODARSTWA WIEJSKIEGO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-08-29

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

SGGW WARSAW UNIVERSITY OF LI...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MACOV Macrophage-based immunotherapy of platinum-resistant ovarian... 2M€ Cerrado

PID2021-124010OB-I00 FARMACOS MULTI-DIANA EN LA INMUNOTERAPIA DEL CANCER: DESCUBR... 145K€ Cerrado

TAM-ADaCT A Novel Antibody-Drug Conjugate for Targeting Tumor-Associat... 150K€ Cerrado

CTQ2015-71506-R CONJUGACION DE MACROLIDOS CON ANTICUERPOS Y DE INHIBIDORES D... 151K€ Cerrado

FJC2019-041213-I Novel immunotherapy for cancer targeting macrophages 50K€ Cerrado

CTQ2016-78454-C2-2-R ANTICUERPOS MONOCLONALES MODIFICADOS CON AGENTES FOTO- Y QUI... 47K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2023-08-29
Fecha Fin: 2025-03-31

Líder del proyecto

SZKOLA GLOWNA GOSPODARSTWA WIEJSKIEGO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Macrophage therapy is promising for solid tumor treatment as these cells are continuously recruited into the tumor mass, even the most hypoxic regions. Our pioneering research demonstrated that macrophages are able to take up ferritins loaded with anti-cancer drugs, creating Macrophage-Drug Conjugates (MDCs), and transfer these to cancer cells and kill them, a phenomenon we named TRAIN. In my ongoing ERC Starting Grant PROJECT ‘McHAP’, we have proven that MDCs can be sucessfully used not only to treat solid tumors but also to induce subsequent resistance to the tumor re-challenge. Acquisition of resistance to tumor development after specific therapy is a 'Golden Grail' in oncology. Now we aim to turn the MDC technology into a commercial and social value proposition by confirming mechanisms of tumor-resistance in tumor-bearing mice and identify immune response. This is crucial to raise interest of and establish a co-development (or licensing) deal with big pharma’s to realize commercialization and clinical uptake of our IP-protected MDC technology. During the ERC PoC project, we will perform high-dimensional spectral flow cytometry, spatial transcriptomics and single-cell transcriptomics of the tumor before and after MDC treatment to identify mechanisms of tumor-resistance and optimize our business case. This project will thus provide proof of concept for the immune activation after the MDC treatment and thus establish the viability, feasibility, commercialization and overall direction for our innovative MDC technology. This project will substantially contribute to bring our MDC technology to the market and clinical practice.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores